-
公开(公告)号：WO2014198951A3
公开(公告)日：2015-08-27
申请号：PCT/EP2014062478
申请日：2014-06-13
Applicant: UCB BIOPHARMA SPRL
Inventor： SHI JIYE , BAKER TERENCE SEWARD , LAWSON ALASTAIR DAVID GRIFFITHS , LIU XIAOFENG
CPC classification number: G06F19/12 , C07K16/244 , C07K2317/55 , C07K2317/76 , G06F19/16 , G06F19/706 , G06F19/709
Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.
Abstract translation: 涉及设计一种将结合大分子靶标的结合位点的配位体或者鉴定对配体的修饰以改善配体对大分子靶标的结合位点的亲和力的方法和相关设备，包括使用关于 从生物大分子数据库中提取的非键合，分子内或分子间或分子间原子与原子接触，以鉴定与特定原子类型的结合位点相邻的有利区域，并修饰候选配体以增加候选配体的原子之间的相交 和优惠地区。 方法的一个或多个步骤可以由计算机执行。
-
公开(公告)号：TN2018000423A1
公开(公告)日：2020-06-15
申请号：TN2018000423
申请日：2017-06-08
Applicant: UCB BIOPHARMA SPRL
Inventor： ADAMS RALPH , CESKA THOMAS ALLEN , DAVIES ANNA MARIE , HENRY ALISTAIR JAMES , LIU XIAOFENG , MCDONNELL JAMES MICHAEL , SUTTON BRIAN JOHN , WESTWOOD MARTA KATARZYNA
IPC: C07K14/735 , C07K16/28 , C07K16/42
Abstract: The present invention relates to the area of improved anti-lgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergie responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of lgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for lgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free lgE and/or IgE complexed with the FcεRl receptor).
-
公开(公告)号：PH12018502574A1
公开(公告)日：2019-10-28
申请号：PH12018502574
申请日：2018-12-06
Applicant: UCB BIOPHARMA SPRL
Inventor： ADAMS RALPH , CESKA THOMAS ALLEN , DAVIES ANNA MARIE , HENRY ALISTAIR JAMES , LIU XIAOFENG , MCDONNELL JAMES MICHAEL; , SUTTON BRIAN JOHN , WESTWOOD MARTA KATARZYNA;
IPC: C07K14/735 , C07K16/28 , C07K16/42
Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the Fc#RI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolairr). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the C#2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the C#2 domain of IgE) and/or the ability to disassociate IgE from the Fc#RI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the Fc#RI receptor).
-
4.发明专利
公开(公告)号：AR108707A1
公开(公告)日：2018-09-19
申请号：ARP170101588
申请日：2017-06-09
Applicant: UCB BIOPHARMA SPRL
Inventor： WESTWOOD MARTA KATARZYNA , SUTTON BRIAN JOHN , MDONNELL JAMES MICHAEL , LIU XIAOFENG , HENRY ALISTAIR JAMES , DAVIES ANNA MARIE , CESKA THOMAS ALLEN , ADAMS RALPH
Abstract: Reivindicación 1: Un anticuerpo anti-IgE o agente de unión al antígeno, que se contacta con un epítopo que comprende, con referencia a la ID. DE SEC. Nº 108, los residuos T373, W374, S375, R376, A377, S378, G379, P381, Q417, C418, R419, T421, P426, R427, A428 de un dominio Ce3 y los residuos D278 y T281 de un dominio Ce2 de la IgE humana. Reivindicación 11: Un anticuerpo anti-IgE o el agente de unión al antígeno, de un modo opcional de acuerdo con las reivindicaciones 1 a 10, que comprende una región variable de cadena pesada que comprende una región determinante de la complementariedad, CDR-H3, con una secuencia de aminoácidos con la Id. de Sec. Nº 18, y una región variable de cadena liviana que comprende una región determinante de la complementariedad, CDR-L1, con una secuencia de aminoácidos con la Id. de Sec. Nº 29, donde la región variable de cadena liviana comprende, asimismo, una región de marco de lectura, FR-L3, con una secuencia de aminoácidos seleccionada de la Id. de Sec. Nº 32 que tiene una, dos, tres, cuatro, cinco, seis, siete o más sustituciones de aminoácidos, para fortalecer la interacción del anticuerpo anti-IgE o del agente de unión al antígeno, con el dominio Ce2 de la IgE humana. Reivindicación 104: Una secuencia de ADN aislada que codifica la o las cadenas pesadas y/o livianas de un anticuerpo anti-IgE o un agente de unión al antígeno, de acuerdo con las reivindicaciones 1 a 103. Reivindicación 105: Un vector de clonación o expresión que comprende una o más secuencias de ADN de acuerdo con la reivindicación 104. Reivindicación 108: Una célula hospedadora que comprende uno o más vectores de clonación o expresión de acuerdo con las reivindicaciones 105 a 107 Reivindicación 111: Una composición farmacéutica que comprende el anticuerpo anti-IgE o el agente de unión al antígeno, de acuerdo con las reivindicaciones 1 a 103, en combinación con uno o más excipientes, diluyentes o portadores farmacéuticamente aceptables. Reivindicación 123: El anticuerpo anti-IgE o el agente de unión al antígeno, de acuerdo con las reivindicaciones 1 a 103, o una composición de acuerdo con las reivindicaciones 102 a 111 para usar en el tratamiento o en la prevención de trastornos asociados con el complejo de la IgE humana y FceRI.
-
公开(公告)号：SG11201804381SA
公开(公告)日：2018-06-28
申请号：SG11201804381S
申请日：2016-12-01
Applicant: UCB BIOPHARMA SPRL
Inventor： BAKER TERENCE SEWARD , LIU XIAOFENG , SHI JIYE , TAYLOR RICHARD DAVID
IPC: G06F19/16
Abstract: Computer-implemented methods of designing an antibody that will bind to a target epitope are disclosed. In one arrangement, the method comprises identifying one or more hotspot residues that will each bind to a corresponding one of one or more hotspot sites on the target epitope. Candidate antibody structures are selected from a database such that characteristic atoms within the antibody structure and hotspot characteristic atoms can be superimposed computationally with an averaged spatial deviation less than a predetermined threshold. A designed antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.
-
Patent Agency Ranking
公开(公告)号：SG10201707917UA
公开(公告)日：2017-10-30
申请号：SG10201707917U
申请日：2014-06-13
Applicant: UCB BIOPHARMA SPRL
Inventor： SHI JIYE , BAKER TERENCE SEWARD , LAWSON ALASTAIR DAVID GRIFFITHS , LIU XIAOFENG
Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.
-
公开(公告)号：CA3006677A1
公开(公告)日：2017-06-08
申请号：CA3006677
申请日：2016-12-01
Applicant: UCB BIOPHARMA SPRL
Inventor： BAKER TERENCE SEWARD , LIU XIAOFENG , SHI JIYE , TAYLOR RICHARD DAVID
IPC: G06F19/16
Abstract: Computer-implemented methods of designing an antibody that will bind to a target epitope are disclosed. In one arrangement, the method comprises identifying one or more hotspot residues that will each bind to a corresponding one of one or more hotspot sites on the target epitope. Candidate antibody structures are selected from a database such that characteristic atoms within the antibody structure and hotspot characteristic atoms can be superimposed computationally with an averaged spatial deviation less than a predetermined threshold. A designed antibody is generated by replacing matching residues with different residues such that a predicted affinity is increased.
-
公开(公告)号：HK1218579A1
公开(公告)日：2017-02-24
申请号：HK16106512
申请日：2016-06-07
Applicant: UCB BIOPHARMA SPRL
Inventor： SHI JIYE , BAKER TERENCE SEWARD , LAWSON ALASTAIR DAVID GRIFFITHS , LIU XIAOFENG
IPC: G06F20060101
-
公开(公告)号：AU2014280055A1
公开(公告)日：2016-01-28
申请号：AU2014280055
申请日：2014-06-13
Applicant: UCB BIOPHARMA SPRL
Inventor： SHI JIYE , BAKER TERENCE SEWARD , LAWSON ALASTAIR DAVID GRIFFITHS , LIU XIAOFENG
Abstract: Methods and associated apparatus involving designing a ligand ab
-
公开(公告)号：SG11201810199WA
公开(公告)日：2018-12-28
申请号：SG11201810199W
申请日：2017-06-08
Applicant: UCB BIOPHARMA SPRL
Inventor： ADAMS RALPH , CESKA THOMAS ALLEN , DAVIES ANNA MARIE , HENRY ALISTAIR JAMES , LIU XIAOFENG , MCDONNELL JAMES MICHAEL , SUTTON BRIAN JOHN , WESTWOOD MARTA KATARZYNA
IPC: C07K16/28 , C07K14/735 , C07K16/42
Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.023 seconds)
